Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 13, 2025
Product Development
Managing Novartis’ pipeline in an era of fast innovation: Vas Narasimhan in conversation
How the pharma CEO views precision medicine, rising challenges in radioligand therapy, and the CAR T immune reset opportunity
BioCentury | Mar 6, 2025
Product Development
Telix’s end-to-end radiopharma ambitions
With a NASDAQ listing, diagnostic revenues, and clinical therapeutics, logistics-forward company aims to own entire disease journey
BioCentury | Jan 14, 2025
Deals
JPM ushers in flurry of biotech deals, headlined by J&J’s Intra-cellular buy
BioCentury’s Deals Report surveys deals by GSK, Idrx, Lilly, Scorpion, Lantheus, Telix, Gilead, Leo, CBC Group and more
BioCentury | Jan 7, 2025
Deals
Irish sale from Wuxi Biologics, Roche looks to Innovent for ADC
BioCentury’s Deals Report: Wuxi Biologics, Hutchmed in asset sales and more
BioCentury | Jan 6, 2025
Regulation
2024 Approvals: Where are the new modalities?
Last year’s new drug approvals by FDA reflect the continued focus on best-in-class drug development
BioCentury | Oct 29, 2024
Product Development
Market reaction to Intellia data suggests perfection remains bar for gene editing
Clinical Report: Celldex advances in a second urticaria type, Eledon’s mAb helps Type I diabetes patients become insulin-independent, and more
BioCentury | Jul 23, 2024
Product Development
Lead-212’s leading players
Decisions about manufacturing and distribution could be make-or-break for drug developers producing their own lead-212
BioCentury | May 31, 2024
Data Byte
FDA’s May approvals: an mRNA RSV vax, a bispecific and biosimilars
Moderna’s mResvia is its first mRNA vaccine approved outside COVID-19 pandemic
BioCentury | Apr 24, 2024
Product Development
Next-wave radiopharmaceuticals: insights from AACR
Fusion added to view of ɑ-emitters in lutetium-experienced patients, as Novartis, RayzeBio gave peeks at programs with broad indication potential
BioCentury | Apr 12, 2024
Product Development
Cambrian explosion of ADCs at AACR24
Conference showcases six emerging ADC payload types, and trends in antigen pairs for bispecific ADCs
Items per page:
1 - 10 of 27